+34 946 941 421
tad_logo_600

TAD is a new drug discovery company committed at discovering medicines to treat ageing and catastrophic human diseases by in vivo PK/PD screening of drugs in humanized mouse models.

We also provide flexible services in vivo to support research projects in drug discovery and biology. These range from one-off in vivo evaluation of drugs to building ad hoc facilities and research teams for mid/long term projects.

Your projects are the centre of our in vivo service business. Whether they are drug discovery programs or biology models, we can offer you practical and affordable solutions either as a Contract Research Organization or as a Research Project Partner:

We design and implement ad hoc facilities for specific projects. The facilities encompass integrated laboratory units gathered around a small dedicated temporary animal facility. These facilities are state-of-the-art, adapted to maximize personnel comfort and of very low maintenance cost…. See FACILITIES

We also recruit and train operative teams to perform experimental protocols according to industrial-quality standards. Stable teams focused in your projects are the most cost-effective investment. They keep experimental systems ongoing ready for your requests on demand. This strategy minimizes the time of experimental cycles and you get your quality results faster than ever. See FACILITIES

Our operative units are located in high-tech environments (e.g. Biscay Science and Technology Park) where we can take advantage of synergistic interactions with expert institutions in imaging, molecular biology, genomics, metabolomics, pharmacology, etc… See WHERE WE ARE

We use our expertise in industrial in vivo PKPD evaluation to speed up your projects in a cost-effective way. By using innovative experimental design and new robust adaptive statistical approaches, we can help you best defining the experimental parameters to achieve your goals and minimizing the cost of in vivo assays. See IN VIVO RESEARCH

TAD offers a service of preliminary PK in immunocompetent and immunodecifient mice. The service is intended to provide rapid assessments of the PK, in blood or target tissues, of new compounds administered to mice by any route. This is an ideal solution, among other potential uses, to select the best compounds for optimizing the design of efficacy studies.

Let’s talk…!!!. It’s easy completing your work with the right in vivo experiments…!!!….

Iñigo Angulo Barturen

Iñigo Angulo Barturen

Founder/Chief Executive Officer

Received a BSc degree in Biology by University of Basque Country (EHU/UPV, Leioa, Basque Country, Spain), a degree as Specialist in Immunology after four-year residence in Hospital Universitario San Carlos, (Madrid, Spain) and a PhD degree in Biology by Universidad Complutense (Madrid, Spain).

Dr. Angulo-Barturen was Head of Preclinical Therapeutic Efficacy at GlaxoSmithKline Tres Cantos Medicines Development Campus. Dr. Angulo-Barturen has experience developing models of efficacy in cancer, inflammation and infectious diseases, particularly in fungal infections, malaria and tuberculosis. In these diseases he developed unique standardized murine models of P. falciparum human malaria and rapid assays of tuberculosis that are routinely utilized to inform human dose predictions by using innovative PK/PD approaches.

Along with his experience leading drug optimization projects in malaria and tuberculosis assets at GlaxoSmithKline, Dr. Angulo-Barturen was Principal Investigator of the GSK-Translational Pharmacology Group funded by Medicines for Malaria Venture (MMV, Geneva, www.mmv.org) and participated as expert in animal models in Orchid (FP7) and PreDict-TB (Innovative Medicines Initiative) projects funded by the European Commission.

María Belén Jiménez-Díaz

María Belén Jiménez-Díaz

Founder/Head of Experimental Research

Received her BsC degree at Universidad de Salamanca (Salamanca, Spain) and her PhD in Biology by Universidad Complutense de Madrid (Madrid, Spain). Dr. Jiménez-Díaz worked two years in HIV research at Hospital Gregorio Marañón and then moved to GlaxoSmitKline where she worked during the last 12 years. Dr. Jiménez-Díaz got her PhD with the development of the non-myelodepleted GSK P. falciparum humanized mouse (Pfalc HuMouse model).

Dr. Jiménez-Díaz was head of the Therapeutic Efficacy Malaria Group. During her tenure in GSK, Dr. Jiménez-Díaz was in charge of the evaluation of antimalarial compounds and operative direction of the GSK-Translational Pharmacology Group funded by Medicines for Malaria Venture.

Joseba Fernández Arribas

Joseba Fernández Arribas

Founder/Head of Operations, Legal and Finance

Received a BSc degree at Law, with specialization in economy, from the University of Deusto (Bilbao, Basque Country, Spain). Attorney at law in his own law firm since 1990, he was specialized in commercial and labour law. Mr. Fernández Arribas has extensive experience in management and consulting for public institutions, particularly in the sports area.

Eider Salazar Agorria

Eider Salazar Agorria

Veterinarian

Received her BCs degree and her PhD in Veterinary Medicine by the Universidad de Zaragoza (Zaragoza, Spain) where she specialized in lentiviral and prion diseases, developing a deep knowledge in histopathology. Dr. Salazar did a 12-month and 3-month research stay at the Veterinary Faculty of Utrecht University (Utrecht, The Netherlands) and the Swiss company allprion AG (Zürich-Schlieren, Switzerland), respectively. Dr. Salazar has also worked at Basque Tissue Biobank as technical coordinator in the Hospital of Basurto (Bilbao, Basque Country, Spain) and as researcher in a mouse model of Angelman Syndrome at University of Basque Country (EHU/UPV, Leioa, Basque Country, Spain).

Rebeca Sánchez Serrano

Rebeca Sánchez Serrano

Research scientist

Received her degree as Laboratory Technician by the Institute of Academic Training of Healthcare Roger de Llúria (Barcelona, Spain). Ms. Sánchez worked for the last five years in the AAALAC International-accredited animal facility of the Biomedical Research Park of Barcelona in the Specific Pathogen Free Area Barrier. In this institution, Ms. Sánchez was responsible of the working group managing large breeding colonies and providing experimental support in experiments with genetically modified mice.

Hazel Gómez Manrique

Hazel Gómez Manrique

Research scientist

Received her degree as Laboratory Technician in Analysis and Control in Chemistry and Biosanitary Clinical Diagnosis by the Chemistry School of Jesuitas (Bilbao, Basque Country, Spain). Ms. Gómez worked for ten years at University of Basque Country (EHU/UPV, Leioa, Basque Country, Spain) where she specialized in cellular and molecular techniques, microscopy, genotyping and functional genomics providing experimental support to different research projects. Ms. Hazel was also responsible of animal welfare and in vivo experimentation with mice.

Juan Rodríguez Cuesta

Juan Rodríguez Cuesta

Designated Veterinarian

Received his DVM by the University of Zaragoza (Spain),  a master in R&D&i of new drugs and his PhD in Pharmacy by the University of Navarra (Spain). Dr. Rodríguez, works as independent consultant in animal health/welfare in biomedical research. Dr. Rodríguez has more than 15 years of experience as veterinarian and manager of animal facilities (LAF) working for public and private institutions, such as the Centre for Research in Applied Pharmacobiology of the University of Navarra (CIFA), the Centre for Cooperative Research in Biosciences (CIC bioGUNE) and pharmaceutical companies (Faes Farma, S.A., Pharmakine, Ltd.).

Dr. Rodríguez is board member of the Spanish Association for Laboratory Animal Science (SECAL) and SECAL´s representative in the Federation of Laboratory Animal Science Associations (FELASA). He is coordinator of the Working Group on “Animal Biosafety Level 3 Facilities Design” of the Spanish Association for Standardization and Certification (AENOR) and coordinator of the Spanish Network of Animal Welfare Officers. Since 2013, he acts as ad-hoc specialist for AAALAC International.

Where Are We?

TAD is located at The Biscay Science and Technology Park (BSTP, Zamudio, Biscay, Basque Country, Spain)

The BSTP was founded in 1985 by Basque institutions and has become a hotspot of high technology companies. The Park has 250 hectares and hosts more than 200 high technology companies in 14 buildings.

The BSTP is 5 min drive from the Bilbao Airport and 10 min away from downtown Bilbao, the capital of Biscay. Moreover, it has two convention centres and several hotels that facilitate international business interactions.

BIC Bizkaia

The TAD facilities are built in the BIC Bizkaia building, which is specifically aimed at promoters and start-ups and is operating since October 2014.

The building has 6000 m2 on two floors. The ground floor has 13 individual modules, and workshops with the necessary equipment for activities of advanced manufacturing and clean technologies.

The first floor has another 18 individual laboratories, devoted to bio-, micro- and nanotechnology projects, equipped with sockets for gases, shelves and other laboratory furniture, as well as offices and warehouse spaces. The first floor has common areas equipped with infrastructure for bio-nano-micro practices: cold storage rooms, clean cell culture rooms equipped with biosafety cabinets, incubators and microscopes, waste storage areas, -80 ºC, cell storage in liquid nitrogen, a dark room for microscopy and photography, gas extraction hoods for safe handling of organic volatile solvents, autoclaves, precision electronic balances, quantitative PCR thermal cyclers, etc…